On Wednesday, 2797 stocks advanced, 1360 declined and 146 remained unchanged on Bombay Stock Exchange with advance decline ratio of 2.05 indicating a positive closing. Moneylife market breadth indicators remained in the neutral territory.
The trend of the major indices on Wednesday’s trading is given in the table below.
On NSE, 97 securities advanced and closed at a new 52-week high whereas 53 securities sank to close at their new 52-week lows. Nifty Media, Nifty Pharma and Nifty Auto were among the biggest losers. Nifty Infrastructure was the only loser.
Lupin (+3.66%) launched Rivaroxaban for Oral Suspension (1 mg/mL) in the U.S., a pediatric anticoagulant bioequivalent to Xarelto®. It treats and prevents blood clots in children, including post-Fontan procedure cases. With USD 11 million in annual sales, the launch strengthens Lupin’s U.S. portfolio in pediatric care.
ICICI Lombard (+0.73%) received a Rs1,901 crore GST demand and penalty order from the CGST Palghar Commissionerate for FY217-22, citing non-payment on co-insurance and reinsurance commissions. Despite prior re-adjudication and GST Council clarifications, the demand was upheld. The company plans to appeal and asserts no impact on operations or management.
Adani Road Transport signed agreements to acquire Yashodhan Highways and KN Highways from DRN Infrastructure, securing 100% ownership pending regulatory approvals. The move aligns with Adani’s strategy to deepen its presence in India’s road infrastructure sector. Post-acquisition, ARTL will control governance and capital structure of both entities.
L&T Technology Services (+1.77%) signed a $100 million multi-year deal with a leading U.S. industrial equipment firm in the semiconductor value chain. The engagement covers product development, platform automation, and AI-driven engineering, with a dedicated Center of Excellence to accelerate digital transformation. This marks a major sustainability milestone for LTTS.
Adani Green Energy (+3.69%)commissioned 112.5 MW of renewable capacity at Khavda, Gujarat, raising its total operational output to 16,598.6 MW. The move reinforces AGEL’s leadership in India’s clean energy transition and supports national solar and wind targets. Power generation began on September 30, following regulatory clearance.
Biocon (+1.60%) Biologics settled patent litigation with Amgen, clearing the way to launch its biosimilars Bosaya™ and Aukelso™—equivalents to Prolia® and Xgeva®—in the U.S. from October 1, 2025. The move expands Biocon’s presence in the U.S. biosimilars market and supports broader access to affordable therapies for osteoporosis and cancer-related bone conditions.
Wockhardt (-1.53%) submitted an NDA to the US FDA for Zaynich™ (Zidebactam-Cefepime), targeting complicated urinary tract infections caused by MDR/XDR Gram-negative bacteria. This marks the first US NDA for a drug fully developed by an Indian firm. Backed by global Phase III data and Fast Track status, Zaynich™ offers a novel mechanism to combat resistant pathogens.
Nibe Ordnance’s subsidiary Globe Forge secured a $64 million contract to supply empty shells to a global defence firm, with execution slated through February 2028. The deal is independent of related-party interests and strengthens Nibe’s presence in the defence manufacturing space.
Tata Communications (-0.01%) deployed its MOVE™ platform to power BSNL’s new eSIM services, enabling remote activation of 2G/3G/4G via QR code and dual-SIM support. This rollout enhances mobile flexibility for millions, especially travelers, and aligns with the Digital India initiative. The platform also scales for future enterprise IoT applications.
SG Finserve (+2.13%) reported a 28% loan book growth in H1 FY25-26, reaching Rs2,878 crore from Rs2,246 crore in March 2025. Quarterly additions of Rs258 crore (Q1) and Rs374 crore (Q2) reflect strong deployment and utilization. With a 52% CAGR since FY22-23 and AA/A1+ ratings from CRISIL and ICRA, SGFL continues to scale efficiently while serving India’s SME and MSME ecosystem.
Shree Digvijay Cement (+2.54%) doubled its annual production capacity to 3.0 million tons with the commissioning of a new Cement Grinding Plant at Sikka-Digvijaygram, Jamnagar, effective 1 October 2025. This expansion supports rising regional demand and underscores the company’s focus on operational excellence and sustainable growth.
Supriya Lifescience (+0.59%) received WHO-GMP certification for inhalation dosages at its Ambernath facility, following a successful audit on September 2, 2025. The certification, granted on September 30, enables global distribution from the site. No violations were reported, and the company expects no material impact on current operations or supply continuity.
Newgen Software (+1.14%) secured a $2.59 million Master Service Agreement with a leading U.S. healthcare firm via its subsidiary Newgen Software Inc. The 3-year deal includes software subscriptions, cloud hosting, and implementation services, reinforcing Newgen’s expansion in the U.S. healthcare tech space through its cloud and automation platforms.
Kirloskar Brothers (+3.87%) secured a major order from Indian Oil Corporation to supply over 14,000 pump sets for retail operations in the oil and gas sector. The contract will be executed within 12 months, with full payment on delivery, reinforcing KBL’s role in India’s energy infrastructure and its reputation for reliable fluid management solutions.
Goodluck India (+2.82%), BATL, and Axiscades formed a strategic alliance to jointly bid for DRDO’s AMCA stealth fighter programme. The MoU, signed on 30th September 2025, combines manufacturing, aerospace, and systems integration expertise to support India’s Atmanirbhar Bharat vision. The AMCA, a fifth-gen indigenous aircraft, aims to elevate India’s air combat capabilities and reduce reliance on foreign platforms.
Indegene (+0.86%) Ireland acuired 100% equity in BioPharm Parent Holding Inc. for up to USD 106 million in an all-cash deal, expected to close on October 1, 2025. The move strengthens Indegene’s omnichannel marketing capabilities in the Life Sciences sector, integrating BioPharm’s data-driven healthcare expertise with Indegene’s digital-first solutions. BioPharm reported USD 38.13 million in 2024 revenue and employs over 90 professionals.
The top gainers and top losers of the major indices are given in the table below:
The closing values of the major Asian indices are given in the table below:
